Morgan Stanley lowered the firm’s price target on Constellation Brands (STZ) to $160 from $176 and keeps an Equal Weight rating on the shares. Fiscal Q2 results were ahead of lowered expectations as Constellation attributed topline weakness to the difficult macro environment, particularly for its core Hispanic consumer. However, the firm also sees structural longer-term headwinds, including health and wellness trends, demographic pressure, cannabis substitution effects, and sustained greater high-end beer competition, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STZ:
- Closing Bell Movers: Constellation Brands up 3% on earnings beat
- Constellation Brands Reports Strong Q2 FY2026 Results
- STZ Earnings: Constellation Brands Rises after Topping Estimates
- Constellation Brands backs FY26 EPS view $11.30-$11.60, consensus $11.44
- Constellation Brands reports Q2 comparable EPS $3.63, consensus $3.41